Zobrazeno 1 - 10
of 128
pro vyhledávání: '"Michael H Cynamon"'
Autor:
Karen G Anthony, Ulrich Strych, Kacheong R Yeung, Carolyn S Shoen, Oriana Perez, Kurt L Krause, Michael H Cynamon, Paul A Aristoff, Raymond A Koski
Publikováno v:
PLoS ONE, Vol 6, Iss 5, p e20374 (2011)
In an effort to discover new drugs to treat tuberculosis (TB) we chose alanine racemase as the target of our drug discovery efforts. In Mycobacterium tuberculosis, the causative agent of TB, alanine racemase plays an essential role in cell wall synth
Externí odkaz:
https://doaj.org/article/3e4a604a5b604dce8355e6a8c3ab559e
Autor:
Marianna Stampolaki, Satish R. Malwal, Nadine Alvarez-Cabrera, Zijun Gao, Mohammad Moniruzzaman, Svitlana O. Babii, Nikolaos Naziris, André Rey-Cibati, Mariana Valladares-Delgado, Andreea L. Turcu, Kyung-Hwa Baek, Trong-Nhat Phan, Hyeryon Lee, Mattheo Alcaraz, Savannah Watson, Mariette van der Watt, Dina Coertzen, Natasa Efstathiou, Maria Chountoulesi, Carolyn M. Shoen, Ioannis P. Papanastasiou, Jose Brea, Michael H. Cynamon, Lyn-Marié Birkholtz, Laurent Kremer, Joo Hwan No, Santiago Vázquez, Gustavo Benaim, Costas Demetzos, Helen I. Zgurskaya, Thomas Dick, Eric Oldfield, Antonios D. Kolocouris
Publikováno v:
ACS Infectious Diseases. 9:342-364
Using up-to-date methods for synthesis and analysis, 51 sulfonamides were prepared for use as tools in antitubercular drug discovery. The synthetic efforts were centered on varying substituents at three key structural units implicated in antimicrobia
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::afb8bd2b82714fb8b532e8e632ce5ea0
Publikováno v:
Open Forum Infectious Diseases. 9
Background Epetraborole (EBO) is a boron-containing oral inhibitor of bacterial leucyl-tRNA synthetase, an essential enzyme in protein synthesis; EBO demonstrates potent activity against nontuberculous mycobacteria. These studies evaluated oral doses
Publikováno v:
Open Forum Infectious Diseases. 9
Background Epetraborole (EBO) is a boron-containing, oral inhibitor of bacterial leucyl-tRNA synthetase, an essential enzyme in protein synthesis; EBO demonstrates potent activity against nontuberculous mycobacteria (NTM). The standard of care therap
Publikováno v:
Open Forum Infectious Diseases. 9
Background Epetraborole (EBO) is a boron-containing, oral inhibitor of bacterial leucyl-tRNA synthetase, an essential enzyme in protein synthesis; EBO demonstrates potent activity against nontuberculous mycobacteria. We evaluated the effects of selec
Publikováno v:
Frontiers in Microbiology, Vol 9 (2018)
The current standard of care therapy for pulmonary Mycobacterium kansasii infection is isoniazid (300 mg/day), rifampin (600 mg/day), and ethambutol (15 mg/kg/day) for 12 months after achieving sputum culture negativity. Rifampin is the key drug in t
Externí odkaz:
https://doaj.org/article/69d6484fc7294b1193160ca1e71e7868
Autor:
Dimitrios Evangelopoulos, Carolyn M. Shoen, Isobella Honeyborne, Simon Clark, Ann Williams, Galina V. Mukamolova, Michael H. Cynamon, Timothy D. McHugh
Publikováno v:
Microorganisms; Volume 10; Issue 2; Pages: 460
Background: The turnaround times for phenotypic tests used to monitor the bacterial load of Mycobacterium tuberculosis, in both clinical and preclinical studies, are delayed by the organism’s slow growth in culture media. The existence of different
Autor:
Douglas S. Kernodle, Michael H. Cynamon, Hiriam O. Gates, Alexandria D. Allen, Miriam Braunstein, Kyi-Toe Tham, Carolyn M. Shoen, Michelle S. DeStefano, Cynthia C. Hager
Publikováno v:
Vaccines, Vol 1, Iss 1, Pp 34-57 (2013)
Early attempts to improve BCG have focused on increasing the expression of prominent antigens and adding recombinant toxins or cytokines to influence antigen presentation. One such modified BCG vaccine candidate has been withdrawn from human clinical
Externí odkaz:
https://doaj.org/article/aaae56e2959f43f2a7bf99aaa49a9511